Novel Small-Molecule ROCK2 Inhibitor GNS-3595 Attenuates Pulmonary Fibrosis in Preclinical Studies
American Journal of Respiratory Cell and Molecular Biology · 2024
DOI: 10.1165/rcmb.2023-0401oc ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Respiratory Cell and Molecular Biology, 2024. Verfasst von Soyoung Hwang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Genosco Inc., Billerica, Massachusetts. Hauptthemen laut MEDLINE: rho-Associated Kinases, Bleomycin. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that leads to respiratory decline caused by scarring and thickening of lung tissues. Multiple pathways contribute to the fibrotic process in this disease, such as inflammation, epithelial-to-mesenchymal transition, and oxidative stress. The Rho-associated coiled-coil forming protein kinase (ROCK) signaling pathway is a key regulator of profibrotic signaling, as it affects the organization of actin-myosin and the remodeling of the extracellular matrix. ROCK1/2, a downstream effector of RhoA, is overexpressed in patients with IPF and is a promising target for IPF therapy. However, because of the hypotensive side effects of ROCK1/2 inhibitors, selective ROCK2 compounds are being explored. In this study, we report the discovery of GNS-3595, a potent and selective ROCK2 inhibitor that has ∼80-fold selectivity over ROCK1 at physiological concentrations of ATP. GNS-3595 effectively inhibited ROCK2-mediated phosphorylation of myosin light chain and reduced the expression of fibrosis-related proteins (e.g., collagen, fibronectin, and α-smooth muscle actin) in various in vitro cellular models. GNS-3595 also prevented transforming growth factor β–induced fibroblast-to-myofibroblast transition. In addition, in a bleomycin-induced mouse model of pulmonary fibrosis, therapeutic exposure to GNS-3595, suppressed lung fibrosis, stabilized body weight loss, and prevented fibrosis-induced lung weight gain. Transcriptome and protein expression analysis from lung tissues showed that GNS-3595 can revert the fibrosis-related gene expression induced by bleomycin. These results indicate that GNS-3595 is a highly potent, selective, and orally active ROCK2 inhibitor with promising therapeutic efficacy against pulmonary fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genosco Inc., Billerica, Massachusetts.
Zitieren
APA
Hwang, S., Lee, W., Ravi, D., Devine, W., Yong, M., Diebold, R. B., Seung, S. A., Ng, N. W., Lee, J., Gupta, A., & Koh, J. S. (2024). Novel Small-Molecule ROCK2 Inhibitor GNS-3595 Attenuates Pulmonary Fibrosis in Preclinical Studies. American Journal of Respiratory Cell and Molecular Biology. https://doi.org/10.1165/rcmb.2023-0401oc
Vancouver
Hwang S, Lee W, Ravi D, Devine W, Yong M, Diebold RB, et al. Novel Small-Molecule ROCK2 Inhibitor GNS-3595 Attenuates Pulmonary Fibrosis in Preclinical Studies. American Journal of Respiratory Cell and Molecular Biology. 2024. doi:10.1165/rcmb.2023-0401oc
BibTeX
@article{Hwang2024,
author = {Hwang, Soyoung and Lee, Wongil and Ravi, Dashnamoorthy and Devine, William and Yong, Miyong and Diebold, R Bruce and Seung, Sang-Ae and Ng, Nicholas W and Lee, Jaekyoo and Gupta, Anu and Koh, Jong Sung},
title = {Novel Small-Molecule ROCK2 Inhibitor GNS-3595 Attenuates Pulmonary Fibrosis in Preclinical Studies},
journal = {American Journal of Respiratory Cell and Molecular Biology},
year = {2024},
doi = {10.1165/rcmb.2023-0401oc}
}
EUVIMED